Understanding childhood cancer development for better cures

Illustration reproduced with permission from The Red Tree by Shaun Tan, Hachette Australia, 2001.

Using multi-omics technologies, single-cell applications and innovative in vitro and in vivo models, we seek for novel druggable vulnerabilities in pediatric cancers with focus on neuroblastoma.

Research

Novel non-mutated copy number driven drug targets in neuroblastoma

SOX11, a co-opted lineage dependency factor in neuroblastoma

News

Events

ANR 2021 (25-26-27 January 2021)

Let's get digital: 25-26-27 January 2021
Events

From neuroblast to Neuroblastoma (June 12th 2019)

Program: nb2NB-v1.

Latest publications

Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma

Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma

9 July 2020

PRL3 enhances T-cell acute lymphoblastic leukemia growth through suppressing T-cell signaling pathways and apoptosis.

PRL3 enhances T-cell acute lymphoblastic leukemia growth through suppressing T-cell signaling pathways and apoptosis.

30 June 2020

A novel TLX1-driven T-ALL zebrafish model: comparative genomic analysis with other leukemia models

A novel TLX1-driven T-ALL zebrafish model: comparative genomic analysis with other leukemia models

26 June 2020

Distinct Notch1 and BCL11B requirements mediate human γδ/αβ T cell development

Distinct Notch1 and BCL11B requirements mediate human γδ/αβ T cell development

7 April 2020